NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/02/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization191.44 mln
Float196 mln
Earnings Date08/17/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-3.17
Reliable
1-Year Forecast
2.05
Transformational upside
Relative Strength
3
/ 100
Severely lagging
Debt / Equity
5.67
Extremely leveraged
ROE
-974
Deeply negative
Business Description
Humacyte, founded in 2004 and based in Durham, North Carolina, creates ready-to-use human tissue products that can be implanted into patients without triggering immune rejection. The company's core technology produces engineered blood vessels designed to repair, reconstruct, or replace damaged vasculature in a wide range of medical situations, from traumatic injuries and kidney dialysis needs to heart surgery and arterial disease. These vessels can also serve as a delivery mechanism for cell-based treatments, such as transplanting insulin-producing cells to help patients with Type 1 diabetes.